Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
Zufferey
Paul Jacques
PJ
Samama
Charles Marc
CM
Rosencher
Nadia
N
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D017558:Elective Surgical Procedures; D017984:Enoxaparin / Q000008:administration & dosage; D019317:Evidence-Based Medicine; D065427:Factor Xa Inhibitors; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011655:Pulmonary Embolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D011744:Pyrimidinones / Q000008:administration & dosage; D018570:Risk Assessment; D012307:Risk Factors; D013450:Sulfones / Q000008:administration & dosage; D013997:Time Factors; D054556:Venous Thromboembolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*
C553657:1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1H)-one; D000925:Anticoagulants; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D011744:Pyrimidinones; D013450:Sulfones